PDSB
PDS Biotechnology Corporation (PDSB)
Healthcare • NASDAQ • $1.25+9.65%
- Symbol
- PDSB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.25
- Daily Change
- +9.65%
- Market Cap
- $69.77M
- Trailing P/E
- N/A
- Forward P/E
- -2.33
- 52W High
- $1.92
- 52W Low
- $0.51
- Analyst Target
- $7.50
- Dividend Yield
- N/A
- Beta
- 1.50
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12…
Company websiteResearch PDSB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.